Page last updated: 2024-11-04

sarpogrelate and Peripheral Arterial Diseases

sarpogrelate has been researched along with Peripheral Arterial Diseases in 7 studies

sarpogrelate: structure given in first source

Research Excerpts

ExcerptRelevanceReference
"Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events."6.61Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials. ( Li, J; Liao, L; Lu, Y; Xie, J; Yu, Q, 2019)
"Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine 2A antagonist, is a widely used antiplatelet agent for the treatment of peripheral arterial disease (PAD)."5.22Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study. ( Ahn, YK; Chae, IH; Chang, KY; Cho, BR; Cho, DK; Choi, D; Choi, S; Chun, K; Han, KR; Hong, BK; Jin, HY; Kang, W; Kim, DI; Kim, DW; Kim, SH; Kim, YJ; Lee, HC; Lee, JW; Lee, NH; Lee, S; Lee, SR; Park, CG; Pyun, W; Shin, JH; Yu, CW, 2016)
"The effect of the prostaglandin I2 analog, beraprost sodium (BPS), on hemodialysis (HD) patients with peripheral arterial disease (PAD) has not been fully elucidated."5.19Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. ( Hidaka, S; Kobayashi, S; Kondoh, M; Miyaji, T; Moriya, H; Nakazawa, R; Ohtake, T; Sato, M, 2014)
" Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months."2.84SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017)
"Sarpogrelate was effective for improving the symptoms of PAD and showed good tolerability without significant adverse events."2.61Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials. ( Li, J; Liao, L; Lu, Y; Xie, J; Yu, Q, 2019)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Han, A1
Lee, T1
Lee, J2
Song, SW1
Lee, SS1
Jung, IM1
Kang, JM1
Gwon, JG1
Yun, WS1
Cho, YP1
Ko, H1
Park, YJ1
Min, SK2
Lu, Y1
Li, J1
Xie, J1
Yu, Q1
Liao, L1
Ahn, S1
Ha, J1
Min, SI1
Kim, SY1
Cho, MJ1
Cho, S1
Ohtake, T2
Sato, M1
Nakazawa, R1
Kondoh, M1
Miyaji, T1
Moriya, H2
Hidaka, S2
Kobayashi, S2
Lee, HC1
Lee, SR1
Han, KR1
Yu, CW1
Park, CG1
Ahn, YK1
Jin, HY1
Kim, DW1
Cho, DK1
Choi, S1
Kim, SH1
Chang, KY1
Lee, S1
Pyun, W1
Lee, NH1
Kang, W1
Hong, BK1
Cho, BR1
Chae, IH1
Shin, JH1
Chun, K1
Kim, DI1
Lee, JW1
Kim, YJ1
Choi, D1
Soga, Y1
Shintani, Y1
Hamasaki, T1
Tomoi, Y1
Takaoka, J1
Suematsu, N1
Yokoi, H1
Ando, K1
Iwagami, M1
Isshiki, R1
Tsutsumi, D1
Mochida, Y1
Ishioka, K1
Oka, M1
Maesato, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606]Phase 4272 participants (Anticipated)Interventional2016-12-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for sarpogrelate and Peripheral Arterial Diseases

ArticleYear
Effects of sarpogrelate hydrochloride on peripheral arterial disease: A meta-analysis of randomized controlled trials.
    Medicine, 2019, Volume: 98, Issue:46

    Topics: Adult; Aged; Ankle Brachial Index; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease; P

2019

Trials

6 trials available for sarpogrelate and Peripheral Arterial Diseases

ArticleYear
A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention.
    Scientific reports, 2023, 02-13, Volume: 13, Issue:1

    Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Drug Therapy, Combination; Femoral Artery; Humans

2023
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
    Trials, 2017, Sep-22, Volume: 18, Issue:1

    Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con

2017
Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2014, Volume: 18, Issue:1

    Topics: Aged; Aged, 80 and over; Cilostazol; Epoprostenol; Female; Heart Rate; Humans; Male; Microcirculatio

2014
Efficacy and Safety of DP-R202 in Patients with Chronic Artery Occlusive Disease: Multicenter Randomized Double-blind Active-controlled Parallel Group Phase III Clinical Study.
    Clinical therapeutics, 2016, Volume: 38, Issue:3

    Topics: Aged; Arteries; Double-Blind Method; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Peri

2016
Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study.
    Cardiovascular intervention and therapeutics, 2017, Volume: 32, Issue:4

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Endovascular Procedures; Female; Femoral Artery; Huma

2017
Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease.
    Renal failure, 2013, Volume: 35, Issue:1

    Topics: Aged; Blood Pressure; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lower Extremity; M

2013